Psychological treatment of social anxiety disorder: a meta-analysis

C. Acarturk[1],*, P. Cuijpers[1,2], A. van Straten[1] and R. de Graaf[2]

[1] *Vrije Universiteit University Amsterdam, Department of Clinical Psychology, Amsterdam, The Netherlands*
[2] *Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, The Netherlands*

Background. Older meta-analyses of the effects of psychological treatments of social anxiety disorder have found that these treatments have moderate to large effects. However, these earlier meta-analyses also included non-randomized studies, and there are many featured studies in this area which were published after the recent meta-analysis.

Method. We conducted a systematic literature search and identified 29 randomized studies examining the effects of psychological treatments, with a total of 1628 subjects. The quality of studies varied. For the analyses, we used the computer program COMPREHENSIVE META-ANALYSIS (version 2.2.021; Biostat, Englewood, NJ, USA).

Results. The mean effect size on social anxiety measures (47 contrast groups) was 0.70, 0.80 on cognitive measures (26 contrast groups) and 0.70 both on depression (19 contrast groups) and general anxiety measures (16 contrast groups). We found some heterogeneity, so we conducted a series of subgroup analyses for different variables of the studies. Studies with waiting-list control groups had significantly larger effect sizes than studies with placebo and treatment-as-usual control groups. Studies aimed at subjects who met Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for social anxiety disorder had smaller effect sizes than studies in which other inclusion criteria were used.

Conclusions. This study once more makes it clear that psychological treatments of social anxiety disorder are effective in adults, but that they may be less effective in more severe disorders and in studies in which care-as-usual and placebo control groups are used.

Introduction

Social anxiety disorder is a highly prevalent disorder (Davidson *et al.* 1993; Kessler *et al.* 1994; Bijl *et al.* 1998; Furmark, 2002; Grant *et al.* 2005) and is associated with losses in quality of life (Stein *et al.* 2000; Wittchen *et al.* 2000), considerable economic costs (Patel *et al.* 2002; Smit *et al.* 2006), high levels of service use (Magee *et al.* 1996; Stein & Kean, 2000) and serious functional impairments in the educational, social and occupational domains (Davidson *et al.* 1993; Kessler *et al.* 1998). In order to decrease the burden on individuals with social anxiety disorder, several psychological treatments have been developed in the past few decades (Deacon & Abramowitz, 2004; Rodebaugh *et al.* 2004), including exposure, cognitive therapy, social skills training, applied relaxation, and several different combinations of these.

The effects of these psychological treatments on social anxiety disorder have been examined in a considerable number of trials since the late 1970s (Fremouw & Zitter, 1978; Shaw, 1979). Throughout this period, studies changed from small and uncontrolled trials (Heimberg *et al.* 1985) to large, high-quality randomized controlled trials (Blomhoff *et al.* 2001). In order to examine and compare the efficacy of these treatments some narrative reviews were conducted (Heimberg, 1989; Chambless & Gillis, 1993). However, it was not possible with those reviews to quantify their effects on social anxiety disorder. Subsequently, four meta-analyses that examined the effects of psychological treatments were published. The first compared the effects of cognitive behavioural therapy to exposure alone (Feske & Chambless, 1995). A little later, Taylor (1996) examined the effectiveness of cognitive behavioural treatments (exposure, cognitive restructuring without

---

* Address for correspondence: C. Acarturk, M.Sc., Department of Clinical Psychology, Vrije Universiteit Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands.

(Email: c.acarturk@psy.vu.nl)

exposure, exposure with cognitive restructuring, and social skills training) on social anxiety disorder. In 1997, Gould *et al.* (1997) added the pharmacological studies to cognitive behavioural treatments and compared these two treatment approaches. The last meta-analysis was similar in design to the previous one (Federoff & Taylor, 2001) and examined the psychological and pharmacological treatments of social anxiety disorder.

These meta-analyses showed that both psychological and pharmacological interventions are effective in the treatment of social phobia and have large effect sizes. All of them indicated that cognitive behavioural therapies were effective. However, they found somewhat different results concerning the superiority of specific interventions. Feske & Chambless (1995) reported that there is no additional benefit of combining exposure and cognitive interventions over exposure therapy alone. Conversely, Taylor (1996) found that the effects of exposure can be increased with cognitive therapy. In line with Feske & Chambless (1995), Gould *et al.* (1997) reported that exposure had a higher effect size than the combination of exposure with cognitive restructuring (cognitive restructuring alone had the lowest effect size). Although all of the earlier meta-analyses indicated that exposure is effective, the contribution of cognitive therapy seems to be a matter of debate. However, a possible explanation for this was reported in the review of Deacon & Abramowitz (2004); there are fewer trials with only cognitive therapy without any behavioural element. Therefore, to make a more strong comparison between cognitive therapies and exposure, the literature needs more studies with treatment conditions with cognitive therapies only.

On the other hand, pharmacological treatments of social anxiety disorder were also found to be effective. Although the most recent meta-analysis found that pharmacological treatments of social anxiety disorder were the most effective treatments at least in the short-term (Blomhoff *et al.* 2001; Federoff & Taylor, 2001; Clark *et al.* 2003; Davidson *et al.* 2004), there is a lack of studies that directly compare the effects of psychological and pharmacological treatments, so we can not make a clear comparison between them.

However, these previous meta-analyses suffer from several limitations (Rodebaugh *et al.* 2004). Most of them also included non-randomized and uncontrolled studies, which may have resulted in an overestimation of the effects. The one meta-analysis that did focus on randomized trials was conducted more than 10 years ago, and since then 14 new studies have been published that were not included in this meta-analysis. Another important shortcoming of earlier meta-analyses is that none of them conducted state-of-the-art analyses of the heterogeneity of the included studies, nor did they conduct subgroup analyses or meta-regression analyses to examine the sources of heterogeneity. Such analyses are important because they may indicate which differences among the studies affect the outcomes (Rodebaugh *et al.* 2004) and may also indicate which treatments are effective in which populations.

We decided, therefore, to conduct a new meta-analysis with 14 new studies, which is about half of the included studies. We wanted to examine whether the positive results of the earlier meta-analyses remain positive when limited to randomized trials and when all new studies in this area are included. We also wanted to study the heterogeneity of the studies and examine which characteristics of the studies are related to the effect sizes.

Method

Identification and selection of studies

Several methods were used to find the studies. First, we conducted a comprehensive literature search in bibliographical databases (from 1966 to January 2007). We examined 1820 abstracts in Pubmed (301 abstracts), PsycINFO (232), EMBASE (682) and the Cochrane Central Register of Controlled Trials (414). In order to find unpublished studies, we also searched Digital Dissertations (191 abstracts). We searched these databases by combining terms that are indicative of psychological treatment (psychotherapy, mental health treatment, psychological treatment, cognitive therapy, behavior therapy, exposure, social skills training, flooding, and relaxation) and social phobia (or social anxiety disorder). Second, we examined the references of the earlier meta-analyses (Feske & Chambless, 1995; Taylor, 1996; Gould *et al.* 1997; Fedoroff & Taylor, 2001) and systematic reviews (Deacon & Abramowitz, 2004; Rodebaugh *et al.* 2004). Third, we examined the references of the retrieved papers. No language restrictions were applied.

We included studies in which (1) the effects of psychological treatments (2) in subjects aged 18 years or older (3) with social phobia (4) were compared with a control condition (5) in a randomized controlled trial.

We included studies which used one of the following definitions: (1) social anxiety disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-III (APA, 1980), DSM-III-R (APA, 1987) or DSM-IV (APA, 1994) criteria; (2) scoring

above a cut-off score on a self-rating or clinician-rated social anxiety disorder questionnaire (Table 1). Although to include studies with different criteria might cause heterogeneity, we did not want to exclude valuable randomized controlled trials. We aimed to solve possible heterogeneity problems by conducting subgroup analysis.

Quality assessment

The validity and quality of the studies were assessed according to the Cochrane Handbook (Higgins & Green, 2005). The four basic criteria were: allocation to conditions is done by an independent (third) party; adequacy of random allocation concealment to respondents; blinding of assessors of outcomes; and completeness of follow-up data.

Meta-analysis

We calculated effect size (Cohen's d) by subtracting (at post-test) the average score of the control group (M_c) from the average score of the experimental group (M_e) and dividing the result by the average of the standard deviations of the experimental and control group (S.D.$_{ec}$; Hedges & Olkin, 1985; Cooper & Hedges, 1994). An effect size of 0.5 thus shows that the mean of the experimental group is half a standard deviation larger than the mean of the control group. Effect sizes of 0.56–1.2 can be assumed to be large, while effect sizes of 0.33–0.55 are moderate, and effect sizes of 0–0.32 are small (Lipsey & Wilson, 1993).

Effect sizes were calculated only from reliable and valid self-rated or observer-rated questionnaires. When means and standard deviations were not reported, we used other statistics (t value, p value) for the calculation of effect sizes. When more than one measure was used, we calculated the mean of the effect sizes for each study. In the studies that compared more than one experimental condition with a control condition, the number of subjects in the control condition was evenly divided over the experimental conditions so that each subject was used only once in the meta-analyses.

We calculated four effect sizes for each study: one measuring social anxiety disorder, another one measuring cognitive distortions, one of depression, and one measuring general anxiety.

The COMPREHENSIVE META-ANALYSES computer program (version 2.2.021; Biostat, Englewood, NJ, USA) was used to calculate the pooled mean effect sizes. Because of the considerable heterogeneity, we calculated the mean effect sizes with the random-effects model. In the random-effects model, it is assumed that the included studies are from populations of studies that differ from each other systematically. In the random-effects model, the effect sizes differ because of the random error within the studies but also because of true variation in effect size from one study to the next.

As indicator of homogeneity, we calculated the Q statistics. A significant Q rejects the null hypothesis of homogeneity and indicates that the variability among the effect sizes is greater than what is likely to have resulted from subject-level sampling error alone. We also calculated the I^2 statistic, which is an indicator of heterogeneity in percentages. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity, with 25% as low, 50% as moderate, and 75% as high heterogeneity (Higgins *et al.* 2003). Moreover, specific methods for subgroup analyses in the COMPREHENSIVE META-ANALYSIS version 2.2.021 were also conducted to see whether their effect sizes differ from each other.

Publication bias was tested by inspecting the funnel plot on primary outcome measures (effects on social anxiety at post-test), and by Duval & Tweedie's trim and fill procedure (Duval & Tweedie, 2000), which yields an estimate of the effect size after the publication bias has been taken into account (as implemented in COMPREHENSIVE META-ANALYSIS, version 2.2.021). We also calculated 'Orwin's fail-safe N'. This number indicates how many studies with an effect size of zero should be found in order to reduce the effect size that is found to a smaller value (e.g. 0.20). A larger N indicates that the effect size found can be further generalized.

Results

Description of studies

A total of 109 papers that possibly met our inclusion criteria were retrieved for further study. A total of 80 studies were excluded: four because the assignment to the conditions was not random; eight were excluded because the interventions were not psychological treatments; and four were excluded because of their clinically irrelevant diagnostic criteria. Moreover, 41 studies had no control group, three studies gave insufficient data to calculate the effect size, fifteen studies were not aimed only at patients with social anxiety disorder but also with other anxiety disorders, and five studies reported data identical to a later study published by the same authors. A total of 29 publications with 30 studies (with 49 separate controlled comparisons) that met inclusion criteria were included in this meta-analysis (Fig. 1). Characteristics of these 30 studies are described in Table 1.

Table 1. *Characteristics of randomized controlled studies examining the effects of psychological treatments on social phobia*

First-named author (year)	Country	Age groups (years)	Target population — Recruit-ment	Diagnosis	Type of SP	Conditions	Subjects (n)	Intervention (number of sessions)	Format	Follow-up	Instrument	DO (%)	ITT/CO
Akillas (1995)	USA	18–41 (University students)	Com	DSM III-R + SAD ⩾ 11		1. Symptom prescription without reframing	15	Prescribed the performance of specific behaviour without logical explanation (3)	IND	Pre, post, 1 month	SAD, FNE, STAIT-T, BDI	NR	NR
						2. Symptom prescription with reframing	16	Prescribed the performance of specific behaviour with logical explanation (3)	IND				
						3. Waiting list	16						
Andersson (2006)	EU	18–67	Com	DSM-IV + SCID (SP-primary) + SPSQ + MADRS-S < 31 on depression and < 4 on suicide items		1. CBT (Internet) + two *in vivo* groups	30	CBT: self-help manual to describe SP and its symptoms, according to CBT (9)	IND + two GRPs	Pre, post, 12 months	LSAS, SPS, SIAS, SPSQ, PRCS/BAI, MADR	3.1	ITT
						2. Waiting list	32						
Ayres study I (1993)	USA	University students	Com	Scored 1 s.d. or more above the mean of PRCA compared with the population of interest	PS	1. Video for PS anxiety	17	Systematic desensitisation (1)	GRP	Pre, post	PRCA, negative thoughts (%)	7.1	CO
						2. Placebo group	18	Film: how to give a speech (1)	GRP				
						3. Control group	17	No treatment					
Ayres study II (1993)	USA	University students	Com	Scored 1 s.d. or more above the mean of PRCA compared with the population of interest	PS	1. Video for PS anxiety	30	Systematic desensitization (1)	IND	Pre, post, 6 months	PRCA, negative thoughts %)	15.5	CO
						2. Placebo group	30	Film: how to give a speech (1)	IND				
						3. Control group	30	No treatment					
Blomhoof (2001)	EU	18–65	Clin + Com	DSM-IV + CGI-SPS ⩾ 4	GSP	1. Exposure/ placebo	91	Homework, symptom-monitoring diary, and new coping strategies (9)	IND	Pre, post	BSPS, FQ-SP, FNE, SPS	7.4	ITT
						2. Placebo	88						
Butler (1984)	EU	18–65	Clin	DSM-III (SP), Scale of Phobic Severity ⩾ 4	GSP	1. Exposure without AM	15	Exposure without managing anxiety (7)	IND	Pre, post, 6 months	SAD, FNE	8.1	CO
						2. Waiting list	15	Associative therapy: how to see the problem objectively (7)	IND				
Clark (2006)	EU	18–60	Clin	DSM-IV (SP)		1. CT	21	CT: restructuring distorted self-imagery, video feedback (14)	IND	Pre, post, 3 and 12 months	SPC, SIAS, LSAS, SPAI-SP, SPWSS, FNE, BAI, BDI	3.2	ITT
						2. Exposure + AR	21						
						3. Waiting list	20	Exposure + AR: exposure, realization training, homework, *in vivo* exercises (14)	IND				
Clark (1991)	EU	18–60	Com	DSM-III-R (SCID), PRCP ⩾ 8	Performance anxiety	1. CBT + placebo	7	CBT: cognitive distortions, coping, exposure (5)	GRP	Pre, post, 1 month	PRCS, FNE, SAD, SSQ	14.7	CO
						2. Placebo	7						
Cunningham (2006)	USA	NR, adults, mean age 42.6	Com	Moderate fear of PS ⩾ 5, no other social fears	PS	1. The Lefkoe method	17	De-condition the stimuli that produce fear (2–5)	IND	Pre, post	SUBSS, PRCS	10.0	CO
						2. Waiting list	19						

Study	Country	Age	Setting	Diagnosis	Subtype	Conditions	n	Treatment	Format	Assessment	Measures	%	Analysis
Davidson (2004)	USA	18–65	Clin	DSM-IV: GSP	GSP	1. Comprehensive CBT	60	Comprehensive CBT: *in vivo* exposure, CR, SST	GRP	Pre, post	BSPS, SPAI,	28.0	ITT
						2. Placebo	59						
Fremouw (1978)	USA	18–24	Com	Upper quartile (⩾80) of PRCA + ⩾16 PRCS	PS	1. Skills training	12	Skills training: modelling, rehearsal and video feedback (5)	GRP	Pre, post, 2 months	PRCS, SAD, PRCA	0	ITT
						2. Cognitive restructuring – relaxation	12	CRT: muscle relaxation, identify and replace negative self-state (5)	GRP				
						3. Waiting list	11						
Gruber (2001)	USA	25–60	Com	ADIS-R: SP (according to DSM-III-R)		1. CBGT	14	CBGT (12)	GRP	Pre, post, 6 months	FNE, BDI, SPAI, SPS, SISST/	14.8	CO
						2. CBGT + CaCBGT	15	CBGT+CaCBGT: cognitive preparation + cognitive debriefing (8)	GRP				
						3. Waiting list	17						
Harvey (2000)	EU	University students	Com	Top 25 % (⩾17) and bottom 25 % (⩽9) of the FNE + < 20 on BDI		1. CP	20	CP: predict before viewing the video and form an image of themselves and then watch it as a stranger (1)	IND	Pre, post	PS, CAWS, BCS	0	ITT
						2. No CP	20		IND				
Haynes-Clements (1984)	USA	University students	Com	⩾10 on the SSI		1. SST	12	SST: cognitive processes and behavioural skills to maximize social interaction (6)	GRP	Pre, post	SAD, FNE, ASBT	0	ITT
						2. Waiting list	12						
Heimberg (1998)	USA	18–65	Clin	DSM-III-R SP		1. CBGT	28	CBGT: automatic thought, logical errors, formulation of rational responses (12)	GRP	Pre, post	SAD, FNE, FQ-SP, SIAS, SPS, SCL-90 R anxiety, depression	54.2	CO
						2. Matching placebo	27						
Hofmann (2004)	USA	⩾18	Clin	DSM-IV SP + ⩾4 on a self-report for PS	PS	1. CBGT	26	CBGT: skills to identify negative cognitions (12)	GRP	Pre, post, 6 months	SPAI, SCQ	22.5	CO
						2. EGT	24	EGT: in-session *in vivo* exposure (12)	GRP				
						3. Waiting list	19						
Jerremalm (1986)	EU	20–60	Clin	Major problem anxiety in a wide range of social situations		1. AR	10	AR: tension- release of the muscles, role- playing (11)	IND	Pre, post	FSS-III, APQ, SSQ, TI, BDI	16.2	CO
						2. SIT	10	SIT: stress-inoculation training without relaxation part (11)	IND				
						3. Waiting list	18						
Kanter (1979)	USA	22–52	Com	Definition of SP		1. Systematic rational restructuring	15	SRR: imagery training, homework (7)	GRP	Pre, post, 9 weeks	SAD, FNE, IBT, STAI-T	16.2	CO
						2. SCD	13	SCD: imagery training and desensitisation (7)	GRP				
						3. SCD + SRR	18		GRP				
						4. Waiting list	16						
Mattick (1989)	Aus	Mean age 41	Com + Clin	DSM-III SP		1. GE	11	GE: graded approach (6)	GRP	Pre, post, 3 months	SIAS, FQ, FNE, SPS, IBT	9.4	CO
						2. CR with exposure	11	GE+CR: to use cognitive techniques during exposure (6)	GRP				
						3. GE + CR	11		GRP				
						4. Waiting list	10						

Table 1 (*cont.*)

First-named author (year)	Country	Age groups (years)	Target population Recruit-ment	Diagnosis	Type of SP	Conditions	Subjects (n)	Intervention (number of sessions)	Format	Follow-up	Instrument	DO (%)	ITT/CO
Mersch (1995)	EU	18–60	Com	DSM-III-R SP		1. Exposure *in vivo*	7	Exposure (14)	IND	Pre, post, 3 and 18 months	FNE, FQ, SIB, IBI, SASSI-N	16.6	CO
						2. IT	7	IT: RET, SST, exposure (14)					
						3. Waiting list	16						
Mörtberg (2006)	EU	<65	Clin	DSM-IV SP (SCID)	GSP/non-GSP	1. ICBGT	13	ICBGT: psycho-education, CR, AR, homework, video-recorded exposure (9)	GRP	Pre, post, 3 and 6 months	LSAS, SPS, BDI, SIAS, FNE, SIDL, SBQ	7.6	CO
						2. Waiting list	13						
Mörtberg (2007)	EU	18–65	Com	DSM-IV SP		1. IGCT	26	IGCT: psycho-education, AR (16)	GRP	Pre, post, 8 and 12 months	FNE, FQ, BR, LSAS, SIAS, SPS, BDI, NC, SPWSS	28.0	ITT
						2. ICT	28	ICT: shorter sessions for 4 months, individual model (16)	IND				
						3. TAU	18	TAU: SSRI with psychiatric care	IND				
Newman (1994)	USA	Mean age 46.5	Com.	DSM-III-R SP (SCID)+speech anxiety ≥7/10	PS	1. Exposure	15	ET: pure performance based (without cognitive intervention) (8)	GRP	Pre, post	PRCS, SAD, SPAI, FNE, CT, STAI-T	8.3	CO
						2. Waiting list	17						
Oosterbaan (2001)	USA	18–65	Com + Clin	DSM-III-R SP (SCID)		1. CT	24	CT: cognitive restructuring, based on the theory of Beck (12)	IND	Pre, post, 2 and 15 months	FQ, ISS, LSAS, SCI, MADRS	22.0	CO
						2. Placebo	19						
Salaberria (1998)	EU	18–54	Clin + Com	DSM-III-R SP (ADIS-R), ≥15 SAD or ≥21 FNE	GSP	1. Self-exposure *in vivo*	24	Self-exposure *in vivo*: break avoidance (8)	GRP	Pre, post, 1, 3, 6 and 12 months	SAD, FNE, BDI	23.0	CO
						2. Self-exposure *in vivo* and CT	24	Self-exposure *in vivo* with CT: exposure with questioning irrational thoughts (8)					
						3. Waiting list	23		GRP				
Schelver (1983)	USA	University students	Com	≥13 on SADS+interpersonal anxiety for minimum of 1 year		1. CT	11	Book – RET (Ellis & Harper, 1975)	IND	Pre, post	SAD, FNE, STAI-T	22.2	CO
						2. Control group	12	No treatment	IND				
Smits (2006)	USA	18–51	Com	DSM-IV SP (CIDI-Auto)	PS	1. Exposure + video feed of performance	19	Video feed of performance (3)	IND	Pre, post, 1 month	LSAS	12.0	CO
						2. Exposure + video feed of audience	20	Reaction of audience (3)	IND				
								No feedback (3)	IND				
						3. Only exposure	23	Information about beta-wave activity					
						4. Placebo	15						

Study	Country	Age	Recruit	Diagnosis	Conditions	N	Treatment content (sessions)	Format	Assessment	Outcome measures	DO%	Analysis
Stangier (2003)	EU	18–65	Clin + Com	DSM-IV SP (SCID)	1. CBGT 2. CBT 3. Waiting list	22 22 21	More in-session experiment (15) Clark & Wells' model (15)	GRP IND	Pre, post, 6 months	SPAI, SPS, SIAS, BDI, BAI, SCL	8.5	ITT
Stravynski (2000)	CN	Adults	Com + Clin	DSM-IV SP (ADIS)	1. IR with SST 2. IR without SST 3. Waiting list	28 32 21	Developing interpersonal skill (14) Practice of target behaviour (14)	IND IND IND	Pre, post, 6 and 12 months	FQ, SAD, FNE, SCL 90 depression, anxiety	11.7	CO
Turner (1994)	USA	18–56	Clin	DSM-III-R SP (ADIS-R)	1. Flooding 2. Placebo drug	26 21	Imaginal and *in vivo* flooding (20) Beta-blocking drug Identical appearance with atenol		Pre, post, 6 months	SPAI	12.1	CO

SP, Social phobia; DO, drop-outs; ITT, intention to treat; CO, completers; Com, community; DSM, Diagnostic and Statistical Manual of Mental Disorders; SAD, Social Avoidance and Distress Scale; IND, individual; FNE, Fear of Negative Evaluation; STAIT-T, State-Trait Anxiety Inventory-Trait; BDI, Beck Depression Inventory; NR, not reported; EU, European Union; SCID, Structured Clinical Interview for Psychiatric Disorders; SPSQ, Social Performance Scale Questionnaire; MADRS-S, Montgomery–Åsberg Depression Rating Scale – Self-rated; CBT, cognitive behavioural therapy; GRP, group; LSAS, Liebowitz Social Anxiety Scale; PRCS, Personal Report on Confidence as a speaker; BAI, Beck Anxiety Inventory; MADR, Montgomery–Åsberg Depression Rating; s.d, standard deviation; PRCA, Personal Report of Communication Apprehension; PS, public speaking phobia; Clin, clinical; CGI-SPS, Clinical Global Impression – Social Phobia Scale; GSP, generalized social phobia; BSPS, Brief Social Phobia Scale; FQ-SP, Fear Questionnaire Social Phobia Scale; AM, anxiety management; CT, cognitive therapy; AR, applied relaxation; SPS, Social Phobia Scale; SPAI-SP, Social Phobia and Anxiety Inventory – social phobia; SPWSS, Social Phobia Weekly Summary Scale; PRCP, Personal Report of Confidence as a Performer; SSQ, Self-Statement Questionnaire; SUBSS, Subjective Units of Bothersome Sensations Scale; CRT, cognitive relaxation therapy; SST, social skills training; ADIS-R, Anxiety Disorders Inventory Schedule–Revised; CBGT, cognitive behavioural group therapy; CaCBGT, computer-assisted cognitive behavioural group therapy; SISST, Social Interactions Self-Statement Test; CP, cognitive preparation; CAWS, Coming Across Well Score; BCS, Behaviors Composite Score; ASBT, Assessment of Self-Statement and Behavior Test; SCL-90 R, Symptom Checklist 90 Revised; EGT, exposure group therapy; SPAI, Social Phobia and Anxiety Inventory; SCQ, Social Cognitions Scale; SIT, Stress Inoculation Training; FSS-III, Fear Survey Schedule III; APQ, Autonomic Perception Questionnaire; TI, Thought Index; SCD, self-control desensitization; SRR, Systematic Rational Restructuring; IBT, Irrational Beliefs Test; STAIT, State-Trait Anxiety Inventory; Aus, Australia; GE, guided exposure; CR, cognitive restructuring; FQ, Fear Questionnaire; IT, integrated treatment; RET, rational emotive therapy; SIB, Scale for Interpersonal Behavior; IBI, Irrational Beliefs Inventory; SASSI-N, Social Anxiety Self-Statements Inventory-negative; ICBGT, intensive cognitive behavioural group therapy; IGCT, intensive group cognitive therapy; SIDL, Symptoms' Influence on Daily Life Scale; SBQ, Social Behaviors Questionnaire; ICT, individual cognitive therapy; TAU, treatment as usual; SSRI, selective serotonin reuptake inhibitor; BR, Belief Rating; NC, Negative Cognitions; CT, Cognitions during the Talk scale; STAI-T, State Trait Anxiety Inventory - trait; IIS, Inventory of Interpersonal Situations; SCI, Social Cognitions Inventory; MADRS, Montgomery–Asberg Depression Rating Scale; SADS, Social Avoidance and Distress Scale; CIDI-Auto, Composite International Diagnostic Interview; SCL, Symptom Checklist; CN, Canada; ADIS, Anxiety Disorders Inventory Schedule; IR, interpersonal relations.

Fig. 1. Selection and inclusion of studies. SAD, Social anxiety disorder.

The studies included a total of 1628 respondents (979 in the treatment conditions and 649 in the control conditions). Selected characteristics of the included studies are described in Table 1. In 16 studies, subjects were recruited from the community, whereas in eight studies subjects were recruited from clinical settings. In the remaining six studies, a mixed recruitment method was reported. Seven studies focused on university students, while the remaining 23 studies were aimed at adults in general. In 21 studies the subjects had to meet diagnostic criteria for social anxiety disorder. The remaining nine studies included subjects who scored high on self-rating social anxiety measures, or used another definition of social anxiety disorder. In 14 comparisons, the psychological treatment was delivered in individual format, while in 15 comparisons a group format was used (in one study, group and individual formats were combined). The number of sessions varied between one and 20. The exclusive psychological treatments were cognitive behavioural therapy (14 conditions), cognitive therapy (four conditions), social skills training (three conditions), relaxation (two conditions), exposure (eight conditions), and other therapies such as symptom prescription with or without reframing, and the Lefkoe method. The Lefkoe method aims to eliminate the beliefs that are formed a long time ago by emphasizing the earlier circumstances. It also de-conditions

the stimuli that produce negative emotions such as fear (Cunningham *et al.* 2006). In the remaining conditions, various combinations of those psychological treatments were applied (Table 1). In 22 studies, psychological treatments were compared with a waiting-list control group, while in seven studies a placebo control group was used; in the remaining study, a treatment-as-usual control group was used.

The quality of the 30 studies varied. Only in four studies was allocation to conditions conducted by an independent party. Concealment of random allocation to respondents was not possible or not reported in any of the studies. Twelve studies reported blinding of assessors, and drop-out rates ranged from 0 to 54.2% (in one study the drop-out rate was not reported). Intention-to-treat analyses were used only in a minority of the studies ($n = 9$) while the majority of the studies ($n = 20$) were limited to completers-only analyses (not reported in one study).

Effects of psychological treatments at post-test

The effects of psychological treatments on social anxiety measures could be compared with a control group in 29 studies with 48 contrast groups. The mean effect size for measures of social anxiety disorder was 0.77 [95% confidence interval (CI) 0.60–0.94, Table 2]. In two studies, the psychological treatments were combined with placebo (Clark, 1991; Blomhoff *et al.* 2001). To check for possible differences, we conducted a meta-analysis without those two studies. The results were comparable (0.80, 95% CI 0.64–0.97, $Q = 82.8$, $p < 0.001$, $I^2 = 45.6\%$) with the results when those two studies were included. Thus, we continued to include them in the following analysis. Heterogeneity was moderate ($Q = 101.1$, $p < 0.001$, $I^2 = 53.5\%$), so we decided to check for the outliers. One study with an unusually high effect size (Cunningham *et al.* 2006) was considered as an outlier, and excluded from all further analyses. The mean effect size for the remaining 47 contrast groups was 0.70 (95% CI 0.56–0.83). The heterogeneity was considerably lower ($Q = 65.6$, $p < 0.01$, $I^2 = 29.8\%$). We have plotted the effect sizes and 95% CIs of the comparisons in Fig. 2.

In eighteen studies (26 contrast groups), the fear of negative evaluation (FNE; Watson & Friend, 1969) was used as an outcome measure. In a meta-analysis in which the results were limited to FNE, comparable results were found ($d = 0.59$, 95% CI 0.39–0.78, $Q = 42.94$, $p < 0.01$, $I^2 = 41.7\%$), as was the case when we examined the effect sizes on the Social Avoidance and Distress Scale (Watson & Friend, 1969; 11 studies, 15 comparisons; $d = 0.83$, 95% CI 0.56–1.10, $Q = 21.33$, $p < 0.05$, $I^2 = 34.4\%$).

Table 2. *Meta-analyses of studies examining the effects of psychological treatments on social phobia* (*with subgroup analyses*), *cognitive, and depression/anxiety measures compared with control conditions at post-test: overall results and subgroup analyses*

		No. of contrast groups	d	95% CI	Q	I^2 (%)	p
Overall effects							
All studies		48	0.769	0.60–0.94	101.13***	53.52	
One study excluded		47	0.698	0.56–0.83	65.55*	29.83	
Only one condition		28	0.594	0.44–0.75	41.51*	34.96	
FNE[a]		26	0.585	0.39–0.78	42.94*	41.78	
SAD[b]		15	0.830	0.56–1.10	21.33 N.S.	34.37	
Cognitive		26	0.796	0.54–1.05	54.03***	53.73	
Depression		19	0.700	0.46–0.94	36.72*	50.99	
General anxiety		16	0.700	0.47–0.93	19.55 N.S.	23.27	
Subgroup analyses							
Control group	Waiting list	35	0.860	0.72–1.00	35.89 N.S.	5.26	***
	Placebo+TAU	12	0.360	0.20–0.52	8.86 N.S.	0.0	
Age groups	Student sample	7	1.057	0.74–1.37	9.39 N.S.	36.11	N.S.
	Adults	40	0.578	0.46–0.69	48.40 N.S.	19.42	
Type of social phobia	General	36	0.611	0.49–0.73	51.57*	32.14	N.S.
	Specific	11	0.732	0.48–0.98	13.25 N.S.	24.55	
Format	Individual	23	0.614	0.47–0.76	46.42*	52.61	N.S.
	Group	24	0.652	0.50–0.81	19.01 N.S.	0.0	
Diagnosis	DSM	35	0.569	0.45–0.69	46.52 N.S.	26.91	**
	Not DSM	12	0.980	0.71–1.25	11.63 N.S.	5.42	
Recruitment	Community	22	0.725	0.55–0.90	22.07 N.S.	4.87	N.S.
	Clinical/community	25	0.578	0.44–0.71	41.78***	42.56	
CBT	CBT	24	0.708	0.56–0.85	35.79*	35.74	N.S.
	Non-CBT	23	0.546	0.39–0.70	27.57 N.S.	20.21	
Exposure	Exposure	8	0.794	0.50–1.09	2.34 N.S.	0	N.S.
	No exposure	39	0.607	0.49–0.72	61.84***	38.55	
Relaxation	Relaxation	8	0.552	0.26–0.85	3.35 N.S.	0	N.S.
	No relaxation	39	0.645	0.53–0.76	61.87*	38.58	
Social skills training	Social skills training	8	0.833	0.60–1.06	13.10 N.S.	46.55	N.S.
	No social skills training	39	0.576	0.46–0.70	48.67 N.S.	21.92	
Analyses	Intention to treat	13	0.448	0.29–0.60	24.96*	51.92	N.S.
	Completers only	32	0.803	0.65–0.95	28.30 N.S.	0	
Follow-up							
1–3 months		20	0.190	0.02–0.36	15.88 N.S.	0.0	
4–6 months		12	0.371	0.12–0.63	19.19 N.S.	42.66	
7–18 months		16	0.148	0.01–0.29	9.23 N.S.	0.0	

CI, Confidence interval; FNE, fear of negative evaluation; SAD, Social Avoidance and Distress Scale; N.S., non-significant; TAU, treatment as usual; DSM, Diagnostic and Statistical Manual of Mental Disorders; CBT, cognitive behavioural therapy.

[a] Only the effects on the FNE were included in this meta-analysis.

[b] Only the effects on the SAD were included in this meta-analysis.

* $p < 0.05$; ** $p < 0.01$, *** $p < 0.001$.

We conducted three more meta-analyses; for cognitive outcomes, depression, and general anxiety measurements. We could compare the effects of the psychological treatments with a control group at post-test on cognitive measurements in 15 studies with 26 contrast groups (Table 2). The mean effect size for cognitive measures was 0.80 (95% CI 0.54–1.05, $Q = 54.0$, $p < 0.001$, $I^2 = 53.7\%$). For self-report measures of depression, we were able to compare 12 studies with 19 contrast groups, which resulted in a mean effect size of 0.70 (95% CI 0.46–0.94, $Q = 36.7$, $p < 0.01$, $I^2 = 50.9\%$). We compared the effects of the psychological treatments on general anxiety measures at post-test in nine studies with 16 contrast groups. The mean effect size was 0.70 (95% CI 0.47–0.93, $Q = 19.6$, N.S., $I^2 = 23.2\%$).

| | | | Statistics for each study | | | | | | | |
Study name (year)	Outcome	S.D. in means	S.E.	Variance	Lower limit	Upper limit	Z	p
Akillas (1995) I	Combined	0.233	0.439	0.193	−0.628	1.095	0.531	0.595
Akillas (1995) II	Combined	1.133	0.463	0.214	0.225	2.041	2.446	0.014
Andersson (2006)	Combined	0.710	0.263	0.069	0.195	1.224	2.702	0.007
Ayres (1993) I	Combined	0.789	0.357	0.127	0.090	1.488	2.212	0.027
Ayres (1993) II	Combined	1.754	0.344	0.118	1.080	2.428	5.101	0.000
Clark (2006) I	Combined	1.967	0.470	0.221	1.046	2.889	4.186	0.000
Clark (2006) II	Combined	0.851	0.407	0.166	0.053	1.649	2.091	0.037
Fremouw (1978) I	Combined	0.638	0.515	0.265	−0.371	1.647	1.240	0.215
Fremouw (1978) II	Combined	0.179	0.501	0.251	−0.803	1.162	0.358	0.720
Gruber (2001) I	Combined	1.149	0.460	0.211	0.248	2.051	2.500	0.012
Gruber (2001) II	Combined	0.708	0.390	0.152	−0.055	1.472	1.818	0.069
Haynes (1984)	Combined	1.395	0.456	0.208	0.502	2.288	3.061	0.002
Hofmenn (2004) I	Combined	0.820	0.385	0.148	0.066	1.574	2.132	0.033
Hofmenn (2004) II	Combined	0.505	0.381	0.145	−0.242	1.252	1.324	0.185
Kanter (1979) I	Combined	1.404	0.564	0.318	0.298	2.510	2.489	0.013
Kanter (1979) II	Combined	0.718	0.540	0.291	−0.340	1.777	1.331	0.183
Kanter (1979 III	Combined	1.015	0.527	0.278	−0.018	2.049	1.925	0.054
Mattick (1989) I	Combined	0.897	0.688	0.474	−0.451	2.246	1.304	0.192
Mattick (1989) II	Combined	0.734	0.687	0.472	−0.612	2.081	1.069	0.285
Mattick (1989) III	Combined	0.996	0.698	0.487	−0.371	2.364	1.428	0.153
Mersch (1995) I	Combined	0.669	0.534	0.286	−0.378	1.717	1.253	0.210
Mersch (1995) II	Combined	0.362	0.523	0.274	−0.663	1.388	0.693	0.488
Mörtberg (2006)	Combined	0.560	0.416	0.173	−0.256	1.376	1.346	0.178
Newman (1994)	Combined	0.727	0.367	0.135	0.008	1.447	1.981	0.048
Selaberria (1998) I	Combined	1.282	0.431	0.186	0.436	2.127	2.972	0.003
Selaberria (1998) II	Combined	1.298	0.432	0.186	0.452	2.144	3.007	0.003
Schelver (1983) I	Combined	1.065	0.540	0.291	0.007	2.123	1.973	0.048
Schelver (1983) II	Combined	0.652	0.512	0.262	−0.351	1.656	1.274	0.203
Smits (2006) I	LSAS	0.561	0.512	0.262	−0.443	1.565	1.095	0.273
Smits (2006) II	LSAS	0.190	0.510	0.260	−0.809	1.189	0.373	0.709
Smits (2006) III	LSAS	0.572	0.513	0.263	−0.433	1.576	1.115	0.265
Stangier (2003) I	Combined	0.104	0.370	0.137	−0.621	0.828	0.281	0.779
Stangier (2003) II	Combined	0.289	0.372	0.138	−0.440	1.017	0.776	0.437
Stravynski (2000) I	Combined	1.186	0.391	0.153	0.420	1.952	3.035	0.002
Stravynski (2000) II	Combined	1.539	0.409	0.167	0.737	2.341	3.762	0.000
Turner (1994)	SPAI	0.930	0.329	0.108	0.285	1.575	2.828	0.005
Blomhoff (2001)	Combined	0.090	0.150	0.022	−0.203	0.384	0.604	0.546
Clark (1991)	Combined	0.100	0.536	0.287	−0.950	1.149	0.186	0.853
Davidson (2004) I	Combined	0.583	0.228	0.052	0.136	1.029	2.558	0.011
Davidson (2004) II	Combined	0.562	0.228	0.052	0.115	1.009	2.463	0.014
Mörtberg (2007) I	Combined	0.253	0.297	0.088	−0.330	0.836	0.851	0.395
Mörtberg (2007) I	Combined	0.419	0.303	0.092	−0.175	1.014	1.383	0.167
Jerremelm (1986) I	a1	0.360	0.570	0.325	−0.757	1.477	0.632	0.528
Jerremelm (1986) II	b1	0.870	0.630	0.397	−0.365	2.105	1.381	0.167
Heimberg (1998)	Combined	0.326	0.280	0.078	−0.223	0.874	1.164	0.244
Oosterbaan (2001)	Combined	0.318	0.309	0.096	−0.288	0.924	1.028	0.304
Butler (1984) I	Combined	0.748	0.378	0.143	0.008	1.488	1.980	0.048
Random		0.698	0.069	0.005	0.562	0.833	10.093	0.000

Fig. 2. Standardized effect sizes of psychological treatments compared with control conditions at post-test. s.d., Standard difference; s.e., standard error; CI, confidence interval; LSAS, Liebowitz Social Anxiety Scale; SPAI, Social Phobia and Anxiety Inventory.

We have included multiple comparisons from one study in our analyses. However, these multiple comparisons are not independent from each other, and this may result in an artificial reduction of heterogeneity. Therefore, we conducted an additional meta-analysis, in which we included only one comparison per study. From the studies with multiple comparisons we included only the comparison with the smallest effect size, because this was considered the most conservative approach in estimating heterogeneity. As can be seen in Table 2, these analyses did indicate that heterogeneity increased somewhat, although the increase was relatively small.

Subgroup analyses

Because we found some heterogeneity, we decided to conduct a series of subgroup analyses for control group (waiting list *versus* placebo/treatment-as-usual), type of analysis (intention-to-treat *versus* completers only), diagnosis (according to diagnostic criteria *versus* scoring above a cut-off score or another measure of social anxiety disorder), age group (university students *versus* adults), type of social anxiety disorder (generalized social anxiety *versus* specific social anxiety disorder), format of intervention (individual *versus* group intervention), recruitment (volunteers from the community *versus* clinical population/both), and type of psychological interventions. We distinguished between interventions in which cognitive restructuring was included *versus* interventions in which this was not included. We also distinguished interventions in which exposure was and was not included; and interventions in which social skills training was and was not included. The results of the analyses are presented in Table 2.

The subgroup analyses resulted in only two subgroups of studies in which the effects sizes differed significantly from each other. Studies with waiting-list control groups had a significantly larger effect size than studies with placebo or treatment-as-usual control groups. Furthermore, studies aimed at subjects who met diagnostic criteria for a social anxiety disorder had a smaller effect size than studies in which other inclusion criteria were used. These two pairs of subgroups also had low to moderate levels of heterogeneity (I^2 in waiting-list control group=5.26; in placebo/treatment-as-usual=0.0; in studies in which diagnostic criteria were used=26.91; in studies in which another definition of social anxiety disorder was used=5.42).

Effects at follow-up

It was not possible to calculate the effects of psychological interventions compared with a control condition at follow-up in any study, because most studies used a waiting-list control condition. Instead, we calculated the effect sizes indicating the difference between post-test and follow-up in the treatment conditions. We could calculate these effect sizes in 20 studies. The follow-up periods ranged from 1 month to 18 months and the effect sizes ranged from −0.022 (at 6 months follow-up) to 2.32 (at 1 month follow-up).

In 10 studies with 20 conditions, the follow-up period was between 1 and 3 months. The resulting pooled random effect size was 0.19 (95% CI 0.02–0.36), indicating a small and a significant improvement from post-test to follow-up. Eight studies with 12 contrast groups also showed a significant change from post-test to 4 to 6 months ($d=0.37$, 95% CI 0.12–0.63). The change between post-test and 7 to 18 months follow-up could also be calculated in nine studies with 16 contrast groups, and resulted in a pooled effect size of 0.15 (95% CI 0.01–0.29), which is a small improvement. These results indicate that the effects of the psychological interventions on social anxiety disorder probably remain stable over time and may even improve somewhat.

Publication bias

The funnel plot and Duval & Tweedie's trim and fill procedure pointed at the possibility of some publication bias. The effect size indicating the difference in social anxiety between treatment and control conditions did not change significantly after adjustment for possible publication bias (observed $d=0.70$, 95% CI 0.56–0.83; adjusted $d=0.45$, 95% CI 0.30–0.60; both with the random-effects model). However, the adjusted value was considerably lower than the observed values, so one must be very careful about a possible overestimation of the mean effect size. The number of studies with a zero effect that should be found in order to reduce the effect size to 0.20 is 102 ('Orwin's fail-safe N'). This large number of unpublished null trials led us to conclude that the present findings were unlikely to be biased by the 'file-drawer' problem.

Discussion

This study showed that a meta-analysis of randomized studies of psychological treatments of social anxiety disorder confirms the findings of earlier meta-analyses that supported the effectiveness of various kinds of psychological treatments of social anxiety disorder in adults (Feske & Chambless, 1995; Taylor, 1996; Gould *et al*. 1997; Federoff & Taylor, 2001). The present findings are important because

almost half of the included studies were not used in the earlier meta-analyses. The overall effect size of 0.70 indicated a large effect of psychological treatments on social anxiety disorder. However, a small to moderate heterogeneity ($I^2 = 29.8\%$) in our meta-analyses pointed at some possible systematic differences among the included studies. Since one of the aims of this study was to explore the sources of heterogeneity, we conducted several subgroup analyses.

Subgroup analyses indicated that studies with pill-placebo or treatment-as-usual control groups had lower effect sizes than the ones with waiting-list control groups. The low heterogeneity of the two subgroups indicated that the overall heterogeneity of the present meta-analysis may be explained by the different control groups of the studies. Additionally, subgroup analyses also indicated that studies which included subjects meeting diagnostic criteria for a social anxiety disorder had significantly lower effect sizes than the studies that used other inclusion criteria. Heterogeneity was zero to low in these subgroups, which may indicate that this difference in diagnostic inclusion criteria may explain the heterogeneity in the overall analyses. In other words, the heterogeneity which is troublesome could be reduced if the researchers include only the studies which were conducted with the subjects who fulfill the diagnostic criteria for social anxiety disorder. Also, these results point at the possibility that social anxiety disorder can be treated better in patients with milder problems, and that treatment is more difficult in patients with more severe disorders. More research is needed to examine this.

We also found that studies in which a waiting-list control group was used had significantly higher effect sizes than studies with a care-as-usual or placebo control group, and in both subgroups very low levels of heterogeneity were found. This is in agreement with other research in other treatment areas where waiting-list control groups typically find higher effect sizes (Cuijpers *et al.* 2007).

We found no indication in our subgroup analyses that the inclusion of cognitive restructuring, exposure, social skills training, or applied relaxation resulted in higher effect sizes. However, most studies used a mix of several of these methods and very few studies examined only one of these techniques. This makes it impossible to draw definite conclusions about the effects of each of these techniques. More research and especially dismantling studies are needed to explore the specific effect of each of these techniques in more detail.

We found one outlier in our meta-analysis, with an unusually high effect size (Cunningham *et al.* 2006). It is not entirely clear why this study had this unusual effect size, but it differs from other studies in that it uses a very specific method (the Lefkoe method). It could be possible that this is a very effective intervention for social speaking anxiety. However, before this can be established, more studies confirming these very high effect sizes should be conducted.

This study has several limitations. First, although our meta-analysis included a relatively large number of studies, we did not have sufficient studies to examine more specific subgroups, such as studies with care-as-usual, placebo control groups, and studies in which subjects were recruited from clinical samples. Second, the quality of several studies was not optimal, and most studies conducted completers-only analysis instead of intention-to-treat analyses.

Despite these limitations, the present meta-analysis suggests that psychological treatments are effective in treating social anxiety disorder in adults, and this effect tends to remain stable to follow-up and may even improve somewhat. Although the number of studies on psychological treatment of social anxiety disorder is relatively high, more research is definitely needed. More research on clinical samples is needed, as well as research in which pill-placebo and treatment-as-usual are used as the control groups. Preferably, these should be high-quality studies with large sample sizes. In order to examine the active components of the psychological treatments, dismantling studies should be conducted.

References

Akillas E, Efran JS (1995). Symptom prescription and reframing: should they be combined? *Cognitive Therapy and Research* **19**, 263–279.

Andersson G, Carlbring P, Holmström A, Sparthan E, Furmark T, Nilsson-Ihrfelt E, Buhrman M, Ekselius L (2006). Internet-based self-help with therapist feedback and *in vivo* group exposure for social phobia: a randomized controlled trial. *Journal of Consulting and Clinical Psychology* **74**, 677–686.

APA (1980). *Diagnostic and Statistical Manual of Mental Disorders*, 3rd edn. American Psychological Association: Washington, DC.

APA (1987). *Diagnostic and Statistical Manual of Mental Disorders*, 3rd edn, revised. American Psychological Association: Washington, DC.

APA (1994). *Diagnostic and Statistical Manual of Mental Disorders*, 4th edn. American Psychological Association: Washington, DC.

Ayres J, Ayres FE, Baker AL, Colby N, de Blasi C, Dimke D, Docken L, Grubb J, Hopf T, Mueller RD, Sharp D, Wilcox AK (1993). Two empirical tests of a videotape designed to reduce public speaking anxiety. *Journal of Applied Communication Research* **21**, 132–147.

Bijl RV, Zessen G, van Ravelli A, de Rijk C, Langendoen Y (1998). The Netherlands Mental Health Survey and Incidence Study (NEMESIS): objectives and design. *Social Psychiatry and Psychiatric Epidemiology* **33**, 581–586.

Blomhoff S, Haug TT, Hellström K, Holme I, Humble M, Madsbu HP, Wold JE (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. *British Journal of Psychiatry: The Journal of Mental Science* **179**, 23–30.

Butler G, Cullington A, Munby M, Amies P, Gelder M (1984). Exposure and anxiety management in the treatment of social phobia. *Journal of Consulting and Clinical Psychology* **54**, 642–650.

Chambless DL, Gillis MM (1993). Cognitive therapy of anxiety disorders. *Journal of Consulting and Clinical Psychology* **61**, 248–260.

Clark DB, Agras WS (1991). The assessment and treatment of performance anxiety in musicians. *American Journal of Psychiatry* **148**, 598–605.

Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J (2006). Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. *Journal of Consulting and Clinical Psychology* **74**, 568–578.

Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B (2003). Cognitive therapy *versus* fluoxetine in generalized social phobia: a randomized placebo-controlled trial. *Journal of Consulting and Clinical Psychology* **71**, 1058–1067.

Cooper H, Hedges LV (1994). *The Handbook of Research Synthesis*. Russell Sage Foundation: New York.

Cuijpers P, van Straten A, Warmerdam L (2007). Problem solving therapies for depression: a meta-analysis. *European Psychiatry* **22**, 9–15.

Cunningham V, Lefkoe M, Sechrest L (2006). Eliminating Fears: an intervention that permanently eliminates the fear of public speaking. *Clinical Psychology and Psychotherapy* **13**, 183–193.

Davidson JRT, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM (2004). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. *Archives of General Psychiatry* **61**, 1005–1013.

Davidson JRT, Hughes DL, George LK, Blazer DG (1993). The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. *Psychological Medicine* **23**, 709–718.

Deacon BJ, Abramowitz JS (2004). Cognitive and behavioral treatments for anxiety disorders: a review of meta-analytic findings. *Journal of Clinical Psychology* **60**, 429–441.

Duval S, Tweedie R (2000). Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* **56**, 455–463.

Ellis A, Harper RA (1975). *A New Guide to Rational Living*. Wilshire Book Company: North Hollywood, CA.

Fedoroff IC, Taylor S (2001). Psychological and pharmacological treatments of social phobia: a meta-analysis. *Journal of Clinical Psychopharmacology* **21**, 311–324.

Feske U, Chambless DL (1995). Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. *Behavior Therapy* **26**, 695–720.

Fremouw WJ, Zitter RE (1978). A comparison of skills training and cognitive restructuring-relaxation for the treatment of speech anxiety. *Behavior Therapy* **9**, 248–259.

Furmark T (2002). Social phobia: overview of community surveys. *Acta Psychiatrica Scandinavica* **105**, 84–93.

Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L (1997). Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. *Clinical Psychology: Science and Practice* **4**, 291–306.

Grant BF, Hasin DS, Blanco C, Stinson FS, Chou SP, Goldstein RB, Dawson DA, Smith S, Saha TD, Huang B (2005). The epidemiology of social anxiety disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Journal of Clinical Psychiatry* **66**, 1351–1361.

Gruber K, Moran PJ, Roth WT, Taylor CB (2001). Computer-assisted cognitive behavioral group therapy for social phobia. *Behavior Therapy* **32**, 155–165.

Harvey AG, Clark DM, Ehlers A, Rapee RM (2000). Social anxiety and self-impression: cognitive preparation enhances the beneficial effects of video feedback following a stressful social task. *Behaviour Research and Therapy* **38**, 1183–1192.

Haynes-Clements LA, Avery AW (1984). A cognitive-behavioral approach to social skills training with shy persons. *Journal of Clinical Psychology* **40**, 710–713.

Hedges LV, Olkin I (1985). *Statistical Methods for Meta-analysis*. Academic Press: San Diego, CA.

Heimberg RG (1989). Cognitive and behavioral treatments for social phobia: a critical analysis. *Clinical Psychology Review* **9**, 107–128.

Heimberg RG, Becker R, Goldfinger K, Vermilyea BA (1985). Treatment of social phobia by exposure, cognitive restructuring, and homework assignments. *The Journal of Nervous and Mental Disease* **173**, 236–245.

Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF (1998). Cognitive behavioral group therapy vs phenelzine therapy for social phobia. 12-week outcome. *Archives of General Psychiatry* **55**, 1133–1141.

Higgins JPT, Green S (2005). *Cochrane Handbook for Systematic Reviews of Interventions* [version 4.2.5, updated May 2005]. John Wiley & Sons, Ltd : Chichester, UK.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. *British Medical Journal* **327**, 557–560.

Hofmann SG (2004). Cognitive mediation of treatment change in social phobia. *Journal of Consulting and Clinical Psychology* **72**, 392–399.

Jerremalm A, Jansson L, Öst LG (1986). Cognitive and physiological reactivity and the effects of different behavioral methods in the treatment of social phobia. *Behaviour Research and Therapy* **24**, 171–180.

Kanter NJ, Goldfried MR (1979). Relative effectiveness of rational restructuring and self-control desensitization in the reduction of interpersonal anxiety. *Behavior Therapy* **10**, 472–490.

Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. *Archives of General Psychiatry* **51**, 8–19.

Kessler RC, Stein MB, Berglund P (1998). Social phobia subtypes in the National Comorbidity Survey. *American Journal of Psychiatry* **155**, 613–619.

Lipsey MW, Wilson DB (1993). The efficacy of psychological, educational and behavioral treatment. *American Psychologist* **48**, 1181–1209.

Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC (1996). Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. *Archives of General Psychiatry* **53**, 159–168.

Mattick RP, Peters L, Clarke JC (1989). Exposure and cognitive restructuring for social phobia : a controlled study. *Behavior Therapy* **20**, 3–23.

Mersch PPA (1995). The treatment of social phobia : the differential effectiveness of exposure *in vivo* and integration of exposure *in vivo*, rational emotive therapy and social skills training. *Behaviour Research and Therapy* **33**, 259–269.

Mörtberg E, Clark DM, Sundin Ö, Wistedt A (2007). Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia : a randomized controlled trial. *Acta Psychiatrica Scandinavica* **115**, 142–154.

Mörtberg E, Karlsson A, Fyring C, Sundin Ö (2006). Intensive cognitive-behavioral group treatment (CBGT) of social phobia : a randomized controlled study. *Journal of Anxiety Disorders* **10**, 646–660.

Newman MG, Hofmann SG, Trabert W, Roth WT, Taylor CB (1994). Does behavioral treatment of social phobia lead to cognitive changes? *Behavior Therapy* **25**, 503–517.

Oosterbaan DB, van Balkom AJLM, Spinhoven P, van Oppen P, van Dyck R (2001). Cognitive therapy versus moclobemide in social phobia : a controlled study. *Clinical Psychology and Psychotherapy* **8**, 263–273.

Patel A, Knapp M, Henderson J, Baldwin D (2002). The economic consequences of social phobia. *Journal of Affective Disorders* **68**, 221–233.

Rodebaugh TL, Holaway RM, Heimberg RG (2004). The treatment of social anxiety disorder. *Clinical Psychology Review* **24**, 883–908.

Salaberria K, Echeburúa E (1998). Long-term outcome of cognitive therapy's contribution to self-exposure *in vivo* to the treatment of generalized social phobia. *Behavior Modification* **22**, 262–284.

Schelver SR, Gutsch KU (1983). The effects of self-administered cognitive therapy on social-evaluative anxiety. *Journal of Clinical Psychology* **39**, 658–667.

Shaw P (1979). A comparison of three behaviour therapies in the treatment of social phobia. *Journal of Clinical Psychopharmacology* **18**, 132–135.

Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A (2006). Excess costs of common mental disorders : population-based cohort study. *Journal of Mental Health Policy and Economics* **9**, 193–200.

Smits JAJ, Powers MB, Buxkamper R, Telch MJ (2006). The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder : a controlled investigation. *Behaviour Research and Therapy* **44**, 1773–1785.

Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM (2003). Cognitive therapy for social phobia : individual versus group treatment. *Behaviour Research and Therapy* **41**, 991–1007.

Stein MB, Kean YM (2000). Disability and quality of life in social phobia : epidemiological findings. *American Journal of Psychiatry* **157**, 1606–1613.

Stein MB, Torgrud LJ, Walker JR (2000). Social phobia symptoms, subtypes, and severity. Findings from a community survey. *Archives of General Psychiatry* **57**, 1046–1052.

Stravynski A, Arbel N, Bounader J, Gaudette G, Lachance L, Borgeat F, Fabian J, Lamontagne Y, Sidoun P, Todorov C (2000). Social phobia treated as a problem in social funcstioning : a controlled comparison of two behavioural group approaches. *Acta Psychiatrica Scandinavica* **102**, 188–198.

Taylor S (1996). Meta-analysis of cognitive-behavioral treatments for social phobia. *Journal of Behavior Therapy and Experimental Psychiatry* **27**, 1–9.

Turner SM, Beidel DC, Jacob RG (1994). Social phobia : a comparison of behavior therapy and atenolol. *Journal of Consulting and Clinical Psychology* **62**, 350–358.

Watson D, Friend R (1969). Measurement of social-evaluative anxiety. *Journal of Consulting and Clinical Psychology* **33**, 448–457.

Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M (2000). Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study. *European Psychiatry* **15**, 46–58.